These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review. Bougea A Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454322 [No Abstract] [Full Text] [Related]
4. Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Ali F; Martin PR; Botha H; Ahlskog JE; Bower JH; Masumoto JY; Maraganore D; Hassan A; Eggers S; Boeve BF; Knopman DS; Drubach D; Petersen RC; Dunkley ED; van Gerpen J; Uitti R; Whitwell JL; Dickson DW; Josephs KA Mov Disord; 2019 Aug; 34(8):1144-1153. PubMed ID: 30726566 [TBL] [Abstract][Full Text] [Related]
5. Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis. Wang H; Wang W; Shi H; Han L; Pan P Medicine (Baltimore); 2020 Oct; 99(40):e21871. PubMed ID: 33019386 [TBL] [Abstract][Full Text] [Related]
6. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882 [TBL] [Abstract][Full Text] [Related]
7. The diagnosis of progressive supranuclear palsy: current opinions and challenges. Ali F; Josephs K Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. Jabbari E; Holland N; Chelban V; Jones PS; Lamb R; Rawlinson C; Guo T; Costantini AA; Tan MMX; Heslegrave AJ; Roncaroli F; Klein JC; Ansorge O; Allinson KSJ; Jaunmuktane Z; Holton JL; Revesz T; Warner TT; Lees AJ; Zetterberg H; Russell LL; Bocchetta M; Rohrer JD; Williams NM; Grosset DG; Burn DJ; Pavese N; Gerhard A; Kobylecki C; Leigh PN; Church A; Hu MTM; Woodside J; Houlden H; Rowe JB; Morris HR JAMA Neurol; 2020 Mar; 77(3):377-387. PubMed ID: 31860007 [TBL] [Abstract][Full Text] [Related]
9. Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers. Parmera JB; Oliveira MCB; Rodrigues RD; Coutinho AM Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):126-136. PubMed ID: 35976324 [TBL] [Abstract][Full Text] [Related]
10. DNA methylation patterns in the frontal lobe white matter of multiple system atrophy, Parkinson's disease, and progressive supranuclear palsy: a cross-comparative investigation. Murthy M; Fodder K; Miki Y; Rambarack N; De Pablo Fernandez E; Pihlstrøm L; Mill J; Warner TT; Lashley T; Bettencourt C Acta Neuropathol; 2024 Jul; 148(1):4. PubMed ID: 38995454 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy. Wenning GK; Colosimo C Rev Neurol (Paris); 2010 Oct; 166(10):829-33. PubMed ID: 20813385 [TBL] [Abstract][Full Text] [Related]
12. Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study. Manna I; Quattrone A; De Benedittis S; Vescio B; Iaccino E; Quattrone A Parkinsonism Relat Disord; 2021 Dec; 93():77-84. PubMed ID: 34839044 [TBL] [Abstract][Full Text] [Related]
14. Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy. Klietz M; Mahmoudi N; Maudsley AA; Sheriff S; Bronzlik P; Almohammad M; Nösel P; Wegner F; Höglinger GU; Lanfermann H; Ding XQ Mov Disord; 2023 Aug; 38(8):1503-1514. PubMed ID: 37289057 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of pain in atypical parkinsonism: a systematic review and meta-analysis. Rana AQ; Qureshi AR; Siddiqui O; Sarfraz Z; Rana R; Shtilbans A J Neurol; 2019 Sep; 266(9):2093-2102. PubMed ID: 30238268 [TBL] [Abstract][Full Text] [Related]
16. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Josephs KA; Dickson DW Mov Disord; 2003 Sep; 18(9):1018-26. PubMed ID: 14502669 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic Approach to Atypical Parkinsonian Syndromes. McFarland NR Continuum (Minneap Minn); 2016 Aug; 22(4 Movement Disorders):1117-42. PubMed ID: 27495201 [TBL] [Abstract][Full Text] [Related]
19. "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Stamelou M; Quinn NP; Bhatia KP Mov Disord; 2013 Aug; 28(9):1184-99. PubMed ID: 23720239 [TBL] [Abstract][Full Text] [Related]
20. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Williams DR; Lees AJ Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]